South San Francisco, California – (work wire) — Maze Therapeutics, a company that translates genetic insights into new precision medicines, announced today that Sekar Kathiresan, managing director of Maze, has joined the company’s board of directors. Dr. Kathiresan is an experienced cardiologist, co-founder and CEO of Verve Therapeutics, and lecturer in medicine at Harvard Medical School. His work focused on making use of human genetics to understand the root causes of diseases and improve preventative care. Among his scientific contributions, Dr. Kathiresan has helped shed light on new biological mechanisms underlying heart attacks, discovered mutations that protect against heart attack risk, and developed a genetic test for personal heart attack prevention.
“Sek has dedicated his career to creating a better understanding of the genetic drivers of cardiovascular disease to deliver better patient care, much in the way that at Maze we have dedicated our research to better understanding the genetic drivers of disease and transforming those insights into Maze’s president and CEO,” said Jason Coloma, Ph.D., president and CEO of Maze. His extensive experience as a practicing cardiologist, scientist and now CEO of biotechnology brings important perspective to Maze as we apply lessons learned from our Compass platform to discover and develop programs for patients in need. We are delighted to welcome him to the Board of Directors, and look forward to partnering with him.”
Dr. said. “As one of the founders of Maze, I am pleased to witness the progress the company has made with its platform and software in just a few short years. Maze has evolved from a concept in 2019 to a company that has already launched a clinical program and continues to develop a strong platform and pipeline. I am proud to join the Board of Directors and contribute in Maze’s continued growth.”
Prior to Verve, Dr. Kathiresan’s roles included director of the Center for Genetic Medicine at Massachusetts General Hospital (MGH), director of the Cardiovascular Disease Initiative at the Broad Institute and professor of medicine at Harvard Medical School. There, Dr. Kathiresan’s research lab focused on understanding the inherited basis of lipids in the blood and myocardial infarction. For his research contributions, he has been honored by the American Heart Association with its highest scientific honor, Distinguished Scientist Award, and the American Society for Human Genetics with the 2018 Kurt Stern Prize. Dr. Kathiresan received his BA in History summa cum laude from the University of Pennsylvania and received his Ph.D. in Medicine from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.
About the labyrinth
Maze Therapeutics is a clinical-stage biopharmaceutical company that applies advanced data science methods combined with a strong suite of research and development capabilities to develop a pipeline of novel precision drugs for patients with genetically defined diseases. Maze has developed Maze Compass™, a proprietary and purpose-built platform that combines human genetic data, functional genomics tools, and data science technology to map new connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression. Using Compass, Maze builds a wide range of wholly owned and partnered software. Maze is located in South San Francisco. For more information, please visit mazetx.com or follow us at LinkedIn And the Twitter.